Published On : July 2026
Regulatory compliance is not a peripheral concern for infectious disease IVD manufacturers, it is often the single largest determinant of how quickly a new test can reach patients and laboratories in a given market. Certification requirements vary substantially by region, and a product cleared in one jurisdiction may require an entirely separate submission pathway, additional clinical performance data, or a different quality management certification before it can be marketed elsewhere. This regulatory complexity sits alongside the global infectious disease IVD market regulatory outlook introduced in the broader market overview, where compliance readiness increasingly functions as a genuine competitive differentiator rather than a background cost of doing business.
This page consolidates the major regulatory pathways relevant to infectious disease IVD products: CE-IVD and IVDR in Europe, FDA pathways in the United States, WHO Prequalification for global health procurement, and the ISO 13485 and ISO 15189 certifications that underpin quality management and laboratory accreditation respectively.
The stakes of regulatory strategy are particularly high in this market because certification decisions are rarely one-time events. Manufacturers must continuously monitor evolving requirements, since regulatory frameworks in this space have shifted meaningfully over the past several years, from the European transition to IVDR to ongoing refinement of FDA review pathways in the wake of the pandemic. Companies that treat regulatory affairs as an ongoing strategic function, rather than a project completed once per product launch, are generally better positioned to respond quickly when requirements change.
The European Union's In Vitro Diagnostic Regulation, or IVDR, replaced the earlier IVD Directive with a substantially more rigorous risk-based classification system. Under IVDR, infectious disease tests are classified according to the risk they pose to individual patients and to public health, with higher-risk categories, such as tests used for blood screening or diagnosing high-consequence pathogens, subject to the most stringent conformity assessment requirements, including mandatory involvement of a notified body.
This shift has extended certification timelines meaningfully compared with the previous directive, since a far larger share of infectious disease tests now require notified body review rather than manufacturer self-certification. It has also raised the bar for post-market surveillance, requiring manufacturers to maintain ongoing clinical performance monitoring rather than treating certification as a one-time milestone.
Manufacturers of CE-IVD certified molecular diagnostic platforms in particular have faced some of the most demanding classification requirements under IVDR, given the high-risk designation typically assigned to molecular tests used in blood screening and high-consequence pathogen detection.
For manufacturers planning a European launch, the practical implication is straightforward. IVDR compliance now needs to be built into product development timelines from the earliest design stage, not treated as a final regulatory checkpoint before launch.
The IVDR transition has also created a significant compliance burden for products that were already on the market under the previous directive, since many of these legacy products require re-certification under the new framework rather than automatic grandfathering. This has led to a wave of re-submission activity across the industry, with some manufacturers choosing to discontinue lower-volume legacy products rather than absorb the cost of re-certifying them under the more demanding IVDR requirements.
For newer market entrants, this dynamic has created an unusual opportunity. Products designed from the outset around IVDR's requirements can sometimes reach the European market on a comparable timeline to established competitors who are still working through legacy product re-certification, narrowing what would otherwise be a significant incumbency advantage.
In the United States, infectious disease IVD products typically reach market through one of several FDA pathways, depending on risk classification and novelty. Many moderate-risk tests proceed through the 510(k) clearance pathway, which requires demonstrating substantial equivalence to an already-cleared predicate device, while higher-risk or genuinely novel tests may require the more rigorous premarket approval, or PMA, pathway.
The pandemic period also established durable precedent around Emergency Use Authorization, a mechanism that allowed accelerated market access for tests addressing urgent public health needs. While EUA pathways are inherently tied to a declared public health emergency, the infrastructure and regulatory familiarity built during that period continue to inform how manufacturers and regulators approach expedited review for future outbreak-relevant diagnostics.
A number of FDA-cleared diagnostic manufacturers maintain broad infectious disease test menus spanning both routine 510(k)-cleared assays and, where relevant, PMA-approved higher-risk molecular platforms.
For manufacturers, understanding which pathway applies to a given test early in development materially affects both the clinical evidence that needs to be generated and the realistic timeline to market.
Beyond the standard 510(k) and PMA pathways, FDA also offers a De Novo classification route for novel, moderate-risk devices that lack an existing predicate but do not warrant the more extensive premarket approval process, and a Breakthrough Devices Program that can accelerate review for tests addressing serious or life-threatening conditions where no adequate alternative exists. Both pathways matter disproportionately for genuinely novel infectious disease diagnostics, such as new multiplex panel designs or first-in-class biomarker-based tests, where a direct predicate device may not exist.
WHO Prequalification is a program run by the World Health Organization to assess the quality, safety, and performance of diagnostic products intended for procurement by United Nations agencies and other international health organizations, particularly for use in lower- and middle-income countries. Prequalified status is frequently a bid condition for large multilateral tenders, meaning a manufacturer without WHO PQ status may be excluded from major public health procurement opportunities regardless of the product's underlying clinical performance.
The prequalification process evaluates both the product itself and the manufacturing site's quality management system, and it is particularly significant for tests targeting diseases such as tuberculosis, HIV, and malaria, where global health procurement represents a substantial share of total addressable demand. For manufacturers targeting these disease categories, WHO PQ is often as commercially consequential as regional regulatory clearance.
For manufacturers with limited resources, deciding whether to pursue WHO Prequalification alongside regional certification is a genuine strategic tradeoff, since the prequalification process requires its own dedicated technical dossier and manufacturing site assessment, separate from, though often informed by, existing CE-IVD or FDA submissions. Companies that plan for WHO PQ from the early stages of product development, rather than pursuing it only after securing regional clearance, generally navigate the process more efficiently, since much of the underlying technical and quality documentation can be prepared in parallel rather than sequentially.
ISO 13485 is the internationally recognized quality management system standard for medical device and IVD manufacturers, covering design controls, risk management, and manufacturing process consistency. It is frequently a prerequisite for regulatory submissions in multiple jurisdictions, since regulators use ISO 13485 certification as evidence that a manufacturer's quality systems meet a baseline international standard.
ISO 15189 addresses a different part of the ecosystem entirely: laboratory accreditation rather than manufacturer certification. It specifies quality and competence requirements for medical laboratories performing the actual testing, covering everything from staff competency to result reporting accuracy. Laboratories seeking ISO 15189 accreditation must demonstrate consistent, validated performance across their testing menu, and accreditation status is increasingly referenced in institutional procurement decisions as a marker of laboratory quality.
The two standards are complementary rather than interchangeable, and confusion between them is a common issue for organizations newer to the sector. A manufacturer generally cannot substitute ISO 15189 laboratory accreditation for its own ISO 13485 quality certification, and a laboratory cannot rely on a manufacturer's ISO 13485 status as a substitute for its own ISO 15189 accreditation. Organizations that operate on both sides of this divide, such as manufacturers running their own reference testing services, typically need to maintain both certifications independently to satisfy the full range of regulatory and institutional buyer expectations.
Beyond the major regional frameworks, individual countries frequently layer additional requirements on top of CE-IVD, FDA, or WHO PQ status, ranging from local language labeling requirements to in-country clinical validation studies or local distributor registration mandates. These country-specific nuances can meaningfully affect launch timelines even after a product has secured its primary regional certification.
Manufacturers expanding into new geographies typically need to budget both time and resources for this secondary layer of country-specific compliance, since assuming that a CE mark or FDA clearance alone guarantees market access in every individual country is one of the more common and costly missteps in international market entry planning.
Regional harmonization efforts are gradually reducing some of this complexity, particularly within trade blocs that have worked to align certification recognition across member countries, though meaningful gaps remain in many parts of the world. Manufacturers with the broadest global footprint generally maintain dedicated regulatory affairs teams organized by region rather than relying on a single centralized function, reflecting the reality that country-specific compliance expertise does not scale easily across a large and varied set of national markets.
What is IVDR and how does it differ from the previous EU IVD Directive?
IVDR is the European Union's In Vitro Diagnostic Regulation, which replaced the earlier IVD Directive with a stricter, risk-based classification system that requires notified body review for a much larger share of infectious disease tests, along with more extensive post-market surveillance obligations.
Is FDA clearance required for all infectious disease IVD tests?
Most infectious disease IVD tests require some form of FDA authorization, whether through the 510(k) clearance pathway for moderate-risk tests, premarket approval for higher-risk or novel tests, or, during declared public health emergencies, Emergency Use Authorization.
What is WHO prequalification and why does it matter for global health programs?
WHO Prequalification is a World Health Organization assessment program confirming that a diagnostic product meets quality, safety, and performance standards for procurement by international health agencies, and it is frequently a required condition for participating in large multilateral public health tenders.
What is the difference between ISO 13485 and ISO 15189 certification?
ISO 13485 certifies a manufacturer's quality management system for producing IVD products, while ISO 15189 accredits medical laboratories for the competence and quality of the testing services they perform.